Med Check |
April 05, 2013
On February 5, Teva Pharmaceutical announced the enrollment of the first patient in the MODERATO study, a phase 4 clinical study designed to evaluate the effect of Azilect (rasagiline tablets) on cognitive function in adults with Parkinson’s disease who also have mild cognitive impairment (PD-MCI).
...[Read More]